Clinical trial
An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment for 48 Weeks in Participants Who Have Completed 96 Weeks of Elvucitabine Therapy in Protocol ACH443-015 or 48 Weeks of Therapy in Protocol ACH443-018
NCT00675844 is registered in ClinicalTrials.gov with Alexion Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment for 48 Weeks in Participants Who Have Completed 96 Weeks of Elvucitabine Therapy in Protocol ACH443-015 or 48 Weeks of Therapy in Protocol ACH443-018
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 31, 2008
- Completion date
- March 31, 2010
- Enrollment
- 7 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.